Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 10/20 | 0.56 |
| ▸ | PPARG | P37231 | 9/20 | 0.56 |
| ▸ | PPARD | Q03181 | 2/20 | 0.56 |
| ▸ | CTSK | P43235 | 4/20 | 0.43 |
| ▸ | CTSS | P25774 | 4/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14586587 | 0.91 | PPARG (0.52) | PPARAPPARGPPARDCTSKCTSS | |
| SCHEMBL14586591 | 0.90 | PPARG (0.51) | PPARAPPARGPPARDCTSKCTSS | |
| SCHEMBL57550 | 0.89 | CTSS (0.49) | PPARAPPARGPPARDCTSKCTSS | |
| SCHEMBL5024738 | 0.89 | CTSS (0.49) | PPARAPPARGPPARDCTSKCTSS | |
| SCHEMBL58394 | 0.89 | CTSS (0.49) | PPARAPPARGPPARDCTSKCTSS | |
| SCHEMBL9963924 | 0.86 | CTSS (0.52) | PPARAPPARGPPARDCTSKCTSS | |
| SCHEMBL18405913 | 0.86 | CTSS (0.52) | PPARAPPARGPPARDCTSKCTSS | |
| SCHEMBL11330590 | 0.83 | CTSS (0.49) | PPARAPPARGPPARDCTSKCTSS | |
| SCHEMBL11330591 | 0.83 | CTSS (0.49) | PPARAPPARGPPARDCTSKCTSS | |
| SCHEMBL3163458 | 0.82 | PPARA (0.52) | PPARAPPARGPPARDCTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070026478-A1 | Hemiasterlin affinity probes and their uses | WYETH (US) | 2007-02-01 | — | — | US | disclosed |
| US-20070026478-A1 | Hemiasterlin affinity probes and their uses | WYETH (US) | 2007-02-01 | — | — | US | disclosed |
| US-20040121965-A1 | Method of treating resistant tumors | WYETH HOLDINGS CORPORATION (US) | 2004-06-24 | — | — | US | disclosed |
| WO-2004047615-A2 | HEMIASTERLIN AFFINITY PROBES AND THEIR USES | WYETH (US) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004026293-A2 | HEMIASTERLIN DERIVATIVES FOR TREATING RESISTANT TUMORS | WYETH HOLDINGS CORPORATION (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070026478-A1 | Hemiasterlin affinity probes and their uses | TUBA1C, TUBB1, TUBB | PPARA 3257/4885PPARG 3111/4885PPARD 3139/4885 |
| US-20040121965-A1 | Method of treating resistant tumors | SLC11A2, VHL, REN | PPARA 1366/4885PPARG 2118/4885PPARD 3609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.